Effect of angiotensin II on pulse wave velocity in humans is mediated through angiotensin II type 1 (AT(1)) receptors

What Was Tested

Researchers studied Angiotensin II in this randomized controlled trial publication.

The objective of this study was to examine the effect of angiotensin II (Ang II) and angiotensin II type 1 (AT(1)) receptor blockade on pulse wave velocity (PWV) in healthy humans.

Why It Was Studied

Subjects thus received placebo capsule + placebo infusion (P), valsartan + placebo infusion (V), placebo + Ang II infusion (A), and valsartan + Ang II infusion (VA) combinations.

Heart rate (HR), blood pressure and PWV were recorded at baseline and then every 10 min during infusion and once after the end of infusion.

Who Took Part

PubMed indexes the participants as adults, men only.

How the Study Was Run

The design is described as randomized, double-blind, placebo-controlled and crossover.

Because people in this Angiotensin II study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the participants and researchers unaware of who received Angiotensin II.

A placebo (an inactive look-alike) gave the Angiotensin II group a baseline to be compared against.

In the crossover set-up each of the participants took both Angiotensin II and the comparison in turn, acting as their own control.

Carotid-femoral PWV (an index of arterial stiffness) was measured by using a Complior machine.

What Was Measured

The subject headings attached to it are Angiotensin II, Angiotensin Receptor Antagonists, Antihypertensive Agents, Blood Flow Velocity, Carotid Arteries, Femoral Artery and Hemodynamics.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Angiotensin II.

The publication is from 2002 (Journal of human hypertension), a journal based in England.

More context: the Angiotensin II compound page, all human trials.